Biosimilar availability is slow coming in US (only RTX, Inflx), but by 2030 these rheumatologic biologics should be available as biosimilars: - rituximab - infliximab - adalimumab - etanercept - golimumab - abatacept - tocilizumab - ustekinumab - denosumab https://t.co/Jjy9xrk4PA https://t.co/4Ht7HSngHQ